Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001829126-26-001059 0001932843 XXXXXXXX LIVE 1 Common Stock, $0.001 par value 05/20/2026 false 0001479419 483119301 KALA BIO, Inc. 1167 Massachusetts Avenue Arlington MA 02476 DAVID E. LAZAR 646-768-8417 44, Tower 100, The Towers Winston Churchill San Francisco Paitilla, Panama City R1 07196 0001932843 N Lazar David E. PF N S1 719404.00 0.00 719404.00 0.00 719404.00 N 3.9 IN Common Stock, $0.001 par value KALA BIO, Inc. 1167 Massachusetts Avenue Arlington MA 02476 Item 3 is hereby amended to add the following: The aggregate purchase price of the 719,404 Shares beneficially owned by the Reporting Person, which consists of Conversion Shares received by the Reporting Person upon the conversion of the Series AA Preferred Stock purchased by the Reporting Person pursuant to the SPA, is $1,308,007. Item 5(a) is hereby amended and restated as follows: The aggregate percentage of Shares beneficially owned by the Reporting Person is based upon 18,589,787 Shares outstanding as of June 9, 2026, as reported in the Form S-3/A filed by the Issuer on June 12, 2026. As of the close of business on the date hereof, the Reporting Person beneficially owned 719,404 Shares. Percentage: 3.9% Item 5(b) is hereby amended and restated as follows: 1. Sole power to vote or direct vote: 719,404 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 719,404 4. Shared power to dispose or direct the disposition: 0 Item 5(c) is hereby amended to add the following: The transactions in the Shares by the Reporting Person during the past sixty days are set forth in Exhibit 1 and are incorporated herein by reference. As of the close of business on April 24, 2026, the Reporting Person ceased to be the beneficial owner of more than 5% of the outstanding Shares. Item 7 is hereby amended to add the following exhibit: 1 Transactions in Securities Lazar David E. /s/ David E. Lazar David E. Lazar 07/02/2026